Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2024-04-23 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：关于召开2023年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2023 Annual General Meeting (AGM) of Shanghai Medicilon Biopharmaceutical Co., Ltd. It includes details such as the date, voting methods, meeting agenda, and instructions for shareholders. It does not contain the actual annual report or financial statements but rather the announcement and logistical information for the AGM. The document length is 3595 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of AGM Information (AGM-R).
2024-04-23 Chinese
美迪西：对外担保管理制度（2024年4月修订）
Governance Information Classification · 95% confidence The document is titled '对外担保管理制度' which translates to 'External Guarantee Management System' and is issued by Shanghai Medicilon Inc. It is a detailed internal policy document outlining the rules, procedures, responsibilities, and disclosure requirements related to the company's external guarantees. It references relevant laws, company bylaws, and regulatory requirements. The document is 6415 characters long, which is substantial and contains detailed procedural and governance content rather than financial data or report results. It is not an announcement of a report, nor a financial statement or earnings release. It is a governance-related internal control and compliance document focused on managing external guarantees and related risks. Therefore, the most appropriate classification is Governance Information (CGR).
2024-04-23 Chinese
美迪西：募集资金管理制度（2024年4月修订）
Capital/Financing Update Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and is issued by Shanghai Medicilon Inc. It details the management, storage, usage, supervision, and changes related to the company's raised funds. The content includes regulatory references, internal control procedures, and compliance with securities laws. It is a detailed policy or management system document rather than a financial report, earnings release, or announcement. It does not contain financial statements or results but focuses on the governance and management of capital raised by the company. This fits best under the category of Capital/Financing Update (CAP), as it relates to the management and use of capital raised through securities issuance and related regulatory compliance.
2024-04-23 Chinese
美迪西：2023年内部控制审计报告
Regulatory Filings
2024-04-23 Chinese
美迪西：关于立信会计师事务所（特殊普通合伙）的履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report on the performance of the auditing firm (立信会计师事务所) for the company's 2023 annual audit. It details the auditor's qualifications, audit procedures, quality management, and overall assessment of the audit work done for the 2023 fiscal year. The document references the 2023 annual audit and the issuance of an unqualified audit report but does not contain the actual financial statements or detailed financial data itself. It is a standalone audit performance evaluation report, not the full annual report or audit report. The length is 3234 characters, which is relatively short and focused on audit firm evaluation rather than financial results. Therefore, it fits best under Audit Report / Information (AR), which includes standalone audit reports and audit firm evaluations, excluding full annual reports. FY 2023
2024-04-23 Chinese
美迪西：2023年年度报告摘要
Annual Report Classification · 100% confidence The document is titled '2023 年年度报告摘要' which translates to '2023 Annual Report Summary' and contains detailed financial data, business overview, industry analysis, risk factors, shareholder information, and management discussion. It includes comprehensive financial figures for multiple years and quarters, detailed descriptions of business operations, industry context, and company strategy. The document length is over 14,000 characters, indicating it is a substantive report rather than a brief announcement. It explicitly states it is a summary derived from the full annual report and provides extensive financial and operational information typical of an Annual Report (10-K). There is no indication that this is merely an announcement or a certification. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-23 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.